Patent Tracker
Applications for patents related to psychedelics have boomed in recent years. Nonprofits, pharmaceutical companies, startups, and academic institutions are all jockeying to patent specific psychedelic compounds and formulations. To help keep tabs on the status of patent applications as they wind their way through the U.S. Patent and Trademark’s review process, BCSP has collaborated on a patent tracker with Psychedelic Alpha, an independent media outlet, community and consultancy firm in the psychedelic field, and Calyx Law, a patent law boutique focusing on cannabis and psychedelics related IP. Read more about the history and process of psychedelic patents here.
1268 Patents
Psilocybin & Psilocin
Title
Methods of treating disorders with a psilocybin analog
Subject Matter
Methods of treating various diseases, disorders, and conditions, such as depressive disorders (e.g., Major Depressive Disorder (MDD)), substance use disorders, anxiety disorders, eating disorders, pain, and headache disorders via administration of deuterated psilocin and pharmaceutically acceptable salts, polymorphs, or solvates thereof.
Psilocybin & Psilocin
Title
Scalable methods of manufacturing psilocybin
Subject Matter
Methods of manufacturing psilocybin and crystalline psilocybin via a reaction of psilocin and tetrabenzylpyrophosphate in the presence of lithium chloride complex Grignard reagent, which is followed by hydrogenation.
Owner
Compass Pathfinder Limited
Patent Number
US20250320240Priority Date
04.12.2024
Status
Published
Psilocybin & Psilocin
Title
Tryptamine compositions for enhancing neurite outgrowth
Subject Matter
Neurotrophic and nootropic compositions and methods for treating subjects with such compositions.
Owner
Turtle Bear Holdings, LLC
Patent Number
US20250325533Priority Date
07.23.2016
Status
Published
Ibogaine
Title
Use of ibogaine in the treatment of central nervous system stroke
Subject Matter
A method for treating the post-acute effects of CNS stroke in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of ibogaine, botanical iboga extract, ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof.
Owner
Ambio Life Sciences Inc.
Patent Number
WO2025208209Priority Date
04.01.2024
Status
PCT Published
Ibogaine
Title
Intravenous administration of ibogaine for treating opioid use disorder
Subject Matter
Methods of treating opioid use disorder in a patient in need thereof by intravenously administering to the patient a therapeutically effective amount of ibogaine or pharmaceutically acceptable salt thereof.
Owner
atai Therapeutics, Inc.
Patent Number
WO2025207633Priority Date
03.25.2024
Status
PCT Published
Psilocybin & Psilocin
Title
Alkaloid materials as a lithium-sulfur battery additives and applications thereof
Subject Matter
Cathodes for use in lithium sulfur batteries (LSB) comprising of a purine compound.
Psilocybin & Psilocin
Title
Scalable methods of manufacturing psilocybin
Subject Matter
Methods of manufacturing psilocybin and crystalline psilocybin via a reaction of psilocin and tetrabenzylpyrophosphate in the presence of lithium chloride complex Grignard reagent, which is followed by hydrogenation.
Owner
Compass Pathfinder Limited
Patent Number
WO2025215243Priority Date
04.10.2025
Status
PCT Published
Psilocybin & Psilocin
Title
Treatment of binge eating disorder using psychedelics
Subject Matter
Methods for treating binge eating disorder (BED) or one or more symptoms thereof, that involve the administration of psychedelics, such as psilocybin, and related uses of the psychedelics.
Psilocybin & Psilocin
Title
Use of benzodiazepines to increase sensitivity to psilocybin following a chronic ssri regimen
Subject Matter
Methods for treating a patient in need thereof comprising co-administering to the patient a therapeutically-effective dose of psilocybin and one or more benzodiazepines.
Owner
Compass Pathfinder Limited
Patent Number
US20250319095Priority Date
10.21.2020
Status
Published
Psilocybin & Psilocin
Title
Methods for the use of psychedelics
Subject Matter
Methods for treating a psychological disorder in a subject comprising administering to the subject an amount of psilocybin or psilocin sufficient to induce a dissociative state in the subject less than 30 minutes after the administration.
Page 1 of 127